Obiettivo
Relieving serious health-related suffering for patients in palliative and end-of-life care, be it physical, psychological, social, or spiritual, is a global ethical responsibility. However, the profound psycho-emotional and existential distress entailed by such suffering, despite often being an enormous burden for both patients and their loved ones, remains a field largely overlooked by health care providers and the scientific community. Those people may develop mood or anxiety disorder for which neither non-pharmacological nor pharmacological interventions exist. In this context, we believe it is now time to target these unmet needs in the palliative care population. We want to initiate a paradigm shift at the boundaries between palliative care, psychiatry, psychology, neuroscience, and spiritual care. Our starting point is the preliminary results being reported for administration of psilocybin, the main psychoactive compound of so-called ‘psychedelic mushrooms’, in patients with depression. The objective of our project is thus to examine the clinical effect of a cutting-edge, individualised and patient-centred, open and standardised Psilocybin Therapy, addressing these unmet needs of patients in palliative care. We will show high quality evidence via a multi-centre Randomised Clinical Trial of the value of our therapeutic model in patients (and for the following four conditions: COPD, Atypical Parkinsonian Disorders, ALS, and Multiple Sclerosis), their loved ones and care providers, in a diverse sample of the European population, in addition to better understand the mechanisms of therapeutic change of our model. Finally, our project will establish a sustainable, multi-disciplinary, ecosystem of key European stakeholders jointly contributing to the medical use of psychedelic research and innovation, paving the way towards an ethical and cost-effective deployment of such a new line of care for patients in European palliative care service providers.
Campo scientifico
Parole chiave
Programma(i)
Argomento(i)
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
9713 GZ Groningen
Paesi Bassi
Mostra sulla mappa
Partecipanti (18)
75647 Uppsala
Mostra sulla mappa
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
1165 Kobenhavn
Mostra sulla mappa
111 37 Stockholm
Mostra sulla mappa
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.
1107TN AMSTERDAM
Mostra sulla mappa
31080 Pamplona
Mostra sulla mappa
751 05 Uppsala
Mostra sulla mappa
1400-038 Lisboa
Mostra sulla mappa
10691 Stockholm
Mostra sulla mappa
9712CP Groningen
Mostra sulla mappa
250 67 Klecany
Mostra sulla mappa
1800 Vilvoorde
Mostra sulla mappa
10430 Rosiere Pres Troyes
Mostra sulla mappa
3400 Hillerod
Mostra sulla mappa
1000 BRUSSELS
Mostra sulla mappa
114 32 STOCKHOLM
Mostra sulla mappa
3818 LE AMERSFOORT
Mostra sulla mappa
67000 Strasbourg
Mostra sulla mappa
106 40 STOCKHOLM
Mostra sulla mappa